Isogenis, Inc.
Contact: John R. Price
Location: Aurora, CO
Email: jprice@isogenis.com
Tel: 720.859.4073
Website: http://www.isogenis.com

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Larta Institute

National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Biopharmaceutical

Company Overview: Founded in 1999, Isogenis, Inc. is a Denver, CO regenerative medicine company advancing novel cell and gene-based therapies for restoring function of damaged organs and tissues. To overcome the interference of the immune system in the success of organ/tissue replacement and gene therapy, the company created and patented *the only, fully deleted, helper-independent Adenoviral vector* that mitigated the immune response risk inherent in early generation Adenoviral vectors.

Isogenis has applied its core technology in the fields of transplantation, gene therapy, tissue engineering and vaccines. Successfully transplants without any adjuvant immune suppressing drugs (such as cyclosporine or FK506) include: organs (pancreatic islets); tissues – engineered skins (incl. heart & lung tissue); cell preparations (hepatocytes); and, most recently, large organs (kidneys).

Target Market(s): Cell and Gene-based Therapy Biopharmaceutical Companies

Key Value Drivers

Technology*: Isogenis holds a robust, economically viable and growing patent estate. Core to the NIH-CAP Program are novel technologies covered by US patents (US 5,601,828 and US 5,623,056) and US patent applications (pending).

Competitive Advantage: The major advantage to this veto approach is our ability to force specific T-Cells that normally attack the transplant to, instead, delete themselves. Rather than suppressing the entire immune system in order to have a viable transplant (and to have special tissue matching), we are only taking out the small number of T-Cells with the ability to reject.

Our innovation overcomes the limitations of efficiency, transgene capacity, inherent toxicity and production of previous viral vector technologies. Greffex's patented technology, engineered veto©, enables the production of tissues able to evade immune rejection by utilizing our novel Adenoviral architecture.

Plan & Strategy: Strategic co-development and corporate development initiatives.

*Technology funded by NIDDK and NIAID and being commercialized under the NIH-CAP

Management

Leadership:

John R. Price, MPA, President and Chief Executive Officer, BS - Trinity University, MPA - Harvard University
Uwe D. Staerz, MD, PhD, Chief Scientific Officer, Chairman of the Board, MD - Eberhard-Karls-Universitaet, Tuebingen, PhD - University of California, San Diego, Professor (2004) – University of Colorado HSC
Miles B. Brennan, PhD, Director Regulatory Affairs, BS – Stanford University PhD - Stanford University

Sir Walter Bodmer, PhD, Chairman Scientific Advisory Board, Principal of Hertford College at Oxford University. Formerly director general and director of research of the Imperial Cancer Research Fund. Fellow of the Royal Society in 1974, knighthood in 1986. Foreign associate of the US National Academy of Sciences, Foreign honorary member of the American Academy of Arts and Sciences.

Product Development

Isogenis, Inc. has invested over 10 years into building a rich technology pipeline across multiple therapeutic platforms.

IND Submission	Q4 '09	Q2 '10	Q4 '10	Q2 '11	Long term
TRANSPLANT AND IMMUNE DISEASE					
Keratinocytes		■			
Hepatocytes		■			
Kidney			■		
Pancreas			■		
EARLY-STAGE PROMISE					
Gene Therapy					
Hemophilia A (Factor VIII)	■				
Parkinson's Disease				■	
Cystic Fibrosis					■
Vaccines					
Vaccination (Infectious Diseases, Cancers – Hepatitis C, Dengue hemorrhagic fever, herpes simplex Type 2)					■
'Negative' Vaccination (Autoimmune diseases – Diabetes mellitus Type I)					■